Form 4 for BNGO Bionano Genomics, Inc.
Accepted 2022-07-11 00:00:00 ET · period of report 2022-07-07 · accession 0001411690-22-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-11 | 2022-07-07 | BNGO | BARKER DAVID L | Dir | M - OptEx | $0.51 | +44.5K | 58.4K | +320% | +$22.7K |
| D | 2022-07-11 | 2022-07-07 | BNGO | BARKER DAVID L | Dir | M - OptEx | $0.00 | -44.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-07 | M | A | 44,470 | $0.51 | 58,364 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-07-07 | M | D | 44,470 | $0.00 | 0 | D | $0.51 · — to 2030-06-30 | 44,470 Common Stock | (F1) The shares vested in equal monthly installments over a one year period such that the option became fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). (F2) The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. |